Half-Year Financial Report
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
ABN: 42 616 305 027
Consolidated Half‐Year Financial Report ‐ 30 June 2021
1
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2021
Directors' Report
The directors present their report, together with the financial statements, on the consolidated entity (referred to
hereafter as the 'consolidated entity') consisting of Imagion Biosystems Limited (referred to hereafter as the 'Company'
or 'parent entity' or ‘Imagion’) and the entities it controlled at the end of, or during the half‐year ended 30 June 2021.
Principal activities
During the financial year the principal continuing activities of the consolidated entity consisted of: Nanotechnology;
Biotechnology; Cancer Diagnostics; and Medical Imaging using Superparamagnetic Relaxometry.
Review of operations
The loss for the consolidated entity after providing for income tax was $1,450,236 (30 June 2020 half‐year: $1,738,496).
Revenue and Other Income comprised interest income, and sales of nanoparticles. The Company markets nanoparticles
to customers and expects to continue to do so, though revenue from this activity is not currently material.
Operating loss of $1,450,236 (30 June 2020 half‐year: $1,738,496 loss) was materially in line with projections and
reduced from 2020 due to: a reduction in research and development expenditure as the Company moved from planning
for the first in‐human‐trial to being open for enrolment; offset by increases in share based payment expenses and an
increase in R&D tax incentives received.
During the half‐year the Company's cash position increased by $0.7 million to $13.9 million as a result of inflows from
the exercise of options and the R&D tax incentive being greater than outflows.
Likely developments and expected results of operations
Management expects spending to increase in future periods pending successful results from the Company's first in‐
human‐trial in relation to HER2 breast cancer which was opened for enrolment in December 2020. If the in‐human‐trial
is successful it is expected spending will increase as the Company moves its focus to a Pivotal Study (Phase III trial). The
Company also expects to carry out other research and development projects throughout the remainder of 2021 and
into 2022.
Significant changes in state of affairs
In June 2021, the consolidated entity received $2,612,159 in R&D tax incentives from the Australian Taxation Office.
Matters subsequent to the end of the financial half‐year
Subsequent to year end the Company entered into a development agreement with Global Cancer Technology to
develop their nanoscintillator technology for the treatment of breast cancer. Under the terms of the agreement,
Imagion will be paid for certain R&D services while gaining an ownership interest in the arising nanoscintillator product.
The timing and quantum of any revenue associated with this agreement is unable to be determined at this stage.
The impact of the Coronavirus (COVID‐19) pandemic is ongoing and while it has not had a significant impact on the
consolidated entity financially up to 30 June 2021 the pandemic has slowed progress with the pace of its Phase I Clinical
Study. It is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation
is constantly evolving and is dependent on measures imposed by the Australian and State‐based Governments.
No other matters or circumstances have arisen since the end of the financial period that has significantly affected or
may significantly affect the operations of the consolidated entity, the results of those operations, or the state of affairs
of the consolidated entity in future financial years.
2
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2021
Rounding of amounts
The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and
Investments Commission, relating to 'rounding‐off'. Amounts in this report have been rounded off in accordance with
that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
On behalf of the directors
Robert Proulx
Executive Chair
17 August 2021
3
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the review of the financial report of Imagion Biosystems Limited and its Controlled Entity for
the half year ended 30 June 2021, I declare that, to the best of my knowledge and belief, there have been no
contraventions of:
(i)
the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
(ii)
any applicable code of professional conduct in relation to the review.
RSM AUSTRALIA PARTNERS
R B MIANO
Partner
Dated: 17 August 2021
Melbourne, Victoria
4
Imagion Biosystems Limited
Consolidated Statement of Profit and Loss and Other Comprehensive Income
For the half‐year ended 30 June 2021
Revenue
Revenue and other income
Research & development tax incentives
Operating Expenses
Research & development expenses
Employment expenses
Professional fees
General expenses
Share based payments expense
Depreciation expense
Foreign exchange gain/(loss)
Finance costs
Loss before income tax expense
Income tax expense (benefit)
Loss after Income Tax Expense
2021
half‐year
$
2020
half‐year
$
168,643
2,612,159
2,780,802
117,093
2,195,551
2,312,644
(1,087,543)
(1,629,047)
(596,221)
(333,890)
(388,906)
(190,316)
(1,960)
(3,155)
(4,231,038)
(1,648,612)
(1,342,288)
(336,214)
(365,248)
(37,326)
(276,584)
(22,425)
(22,443)
(4,051,140)
(1,450,236)
(1,738,496)
‐
‐
(1,450,236)
(1,738,496)
169,080
33,164
‐
‐
169,080
33,164
(1,281,156)
(1,705,332)
Cents
(0.0014)
(0.0014)
Cents
(0.0029)
(0.0029)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Foreign currency translation reserve
Income tax relating to these items
Other comprehensive income/(loss), net of tax
Total comprehensive Income (loss) for the year Attributable to the
Owners of Imagion Biosystems Limited
Basic earnings (loss) per share
Diluted earnings (loss) per share
These financial statements should be read in conjunction with the accompanying notes.
5
Imagion Biosystems Limited
Consolidated Statement of Financial Position
As at 30 June 2021
Note
30‐Jun‐2021
$
31‐Dec‐2020
$
Current Assets
Cash and cash equivalents
Trade and other receivables
Other current assets
Total Current Assets
13,928,123
70,835
358,680
14,357,638
13,200,547
‐
233,440
13,433,987
Non‐Current Assets
Property, plant and equipment
Right‐of‐use assets
Other non‐current assets
Total Non‐Current Assets
128,033
146,171
93,500
367,704
160,432
524,585
‐
685,017
14,725,342
14,119,004
Current Liabilities
Trade and other payables
Lease liabilities
Employee benefits
Other liabilities
Total Current Liabilities
749,771
157,507
136,502
33,022
1,076,802
402,090
358,230
109,095
31,438
900,853
Non‐Current Liabilities
Lease liabilities (NCA)
Employee benefits
Total Non‐Current Liabilities
37,919
2,101
40,020
302,748
1,536
304,284
Total Liabilities
1,116,822
1,205,137
Net Assets
13,608,520
12,913,867
52,909,029
2,159,275
(41,459,784)
13,608,520
51,322,126
1,601,289
(40,009,548)
12,913,867
Total Assets
Equity
Issued capital
Reserves
Accumulated losses
Total Equity
2
3
These financial statements should be read in conjunction with the accompanying notes.
6
Imagion Biosystems Limited
Consolidated Statement of Changes in Equity
For the half‐year ended 30 June 2021
Balance as at 1 January 2020
Issued
Capital
$
36,904,580
Reserves
$
Accumulated
Losses
$
Total Equity
$
714,478
(34,645,541)
2,973,517
Loss after income tax
Other comprehensive income/(loss) after tax
‐
‐
‐
33,164
(1,738,496)
‐
(1,738,496)
33,164
Total comprehensive income/(loss)
‐
33,164
(1,738,496)
(1,705,332)
Transactions with owners in their capacity as owners
Contributions of equity
2,501,480
Costs of contributions of equity
(295,228)
Transfer from reserves
21,875
Share based payments
‐
Balance as at 30 June 2020
39,132,707
‐
‐
(21,875)
71,990
797,757
‐
‐
‐
‐
(36,384,037)
2,501,480
(295,228)
‐
71,990
3,546,427
Issued
Capital
$
Reserves
$
Accumulated
Losses
$
Total Equity
$
51,322,126
1,601,289
(40,009,548)
12,913,867
Balance as at 1 January 2021
Loss after income tax
Other comprehensive income/(loss) after tax
‐
‐
‐
169,080
(1,450,236)
‐
(1,450,236)
169,080
Total comprehensive income/(loss)
‐
169,080
(1,450,236)
(1,281,156)
‐
‐
‐
388,906
2,159,275
‐
‐
‐
‐
(41,459,784)
1,588,825
(1,922)
‐
388,906
13,608,520
Transactions with owners in their capacity as owners
Contributions of equity
1,588,825
Costs of contributions of equity
(1,922)
Transfer from reserves
‐
Share based payments
‐
Balance as at 30 June 2021
52,909,029
These financial statements should be read in conjunction with the accompanying notes.
7
Imagion Biosystems Limited
Consolidated Statement of Cash Flows
For the half‐year ended 30 June 2021
Note
2021
half‐year
$
2020
half‐year
$
88,605
(3,413,015)
12,970
(13,221)
2,612,159
(712,502)
122,610
(3,635,492)
1,132
(18,492)
2,195,551
(1,334,691)
Cash Flows from Investing Activities
Payment for property, plant and equipment
Payment for other assets (security deposits)
Net cash outflow from investing activities
(20,145)
(91,259)
(111,404)
‐
‐
‐
Cash Flows from Financing Activities
Proceeds from the issue of shares
Proceeds from the exercise of options
Transaction costs relation to the issue of shares
Loan from US Government authority
Lease repayments
Net cash inflow from financing activities
‐
1,588,825
(2,114)
‐
(208,366)
1,378,345
2,261,757
‐
(66,762)
233,815
(163,576)
2,265,234
Net increase (decrease) in cash and cash equivalents
554,439
930,543
Cash and cash equivalents at start of year
Effects of exchange rate changes on cash and cash equivalents
13,200,547
173,137
3,401,713
(5,330)
Cash and cash equivalents at end of year
13,928,123
4,326,926
Cash Flows from Operating Activities
Receipts from customers (inc of sales and other taxes)
Payments to suppliers and employees (inc of sales and other taxes)
Interest received
Interest and other finance costs paid
Government grants and tax incentives
Net cash outflow from operating activities
These financial statements should be read in conjunction with the accompanying notes.
8
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2021
1
Significant accounting policies
These general purpose financial statements for the interim half‐year reporting period ended 30 June 2021 have
been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the
Corporations Act 2001, as appropriate for for‐profit entities. Compliance with AASB 134 ensures compliance with
International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
All amounts are stated in Australian dollars, unless otherwise stated.
These general purpose financial statements do not include all the notes of the type normally included in annual
financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report
for the year ended 31 December 2020 and any public announcements made by the Company during the interim
reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.
Going Concern
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal
business activities and the realisation of assets and discharge of liabilities in the normal course of business.
As disclosed in the financial statements, the consolidated entity incurred a loss of $1,450,236 and had net cash
outflows from operating activities of $712,502 for the half‐year ended 30 June 2021. The consolidated entity is still
in the product development phase recording minimal sales revenue, consequently it is dependent on external
funding to cover ongoing product development and has forecast losses for the next financial year.
Despite this financial position, the Directors believe that there are reasonable grounds to believe that the
consolidated entity will be able to continue as a going concern after considering the following factors:
•
•
•
The consolidated entity has a proven record of being able to raise funds to support its ongoing activities
including successfully raising $14.8 million (net of costs) during 2020 from a combination of rights issues,
placements and exercises of options;
The consolidated entity is expecting to receive further material funds upon the exercise of listed options in the
next 12 months;
The consolidated entity has historically received some cost relief through the receipt of research &
development income tax incentives and the directors expect this to continue.
Issued capital
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net
of tax, from the proceeds.
Share Based Payments
The consolidated entity operates an equity settled share based payment employee incentive scheme. The fair value
of the equity to which employees became entitled is measured at grant date and recognised as an expense over the
vesting period, with a corresponding increase to an equity account.
The cost of transactions settled by share based payments is measured at the fair value of the equity instrument at
the date of the issue, using an appropriate market based valuation model.
9
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2021
1
Significant accounting policies (continued)
Comparatives
The comparative results presented refer to the 6‐month period up to 30 June 2020 for the Statement of Profit or
Loss and Other Comprehensive Income and the Statement of Cash Flows. The Statement of Financial Position
contains a comparative Statement of Financial Position as of the end of the immediately preceding reporting period,
being 31 December 2020.
2
Issued capital
2021
Shares
1,042,664,929
2020
Shares
998,367,288
2021
$
52,909,029
2020
$
51,322,126
Movements in ordinary share capital ‐ 6 months to 30 June 2021
Details
Date
balance
1‐Jan‐21
Opening
15‐Feb‐20
Issue of shares (exercise of supplier options)
Issue of shares (exercise of listed options)
Various
Issue of shares (exercise of listed options)
Various
Costs of issue (supplier options)
Various
30‐Jun‐21
Shares
998,367,288
2,986,604
28,027,944
13,283,093
‐
1,042,664,929
Issue Price
‐
0.028
0.030
0.050
‐
$
51,322,126
83,827
840,838
664,160
(1,922)
52,909,029
Ordinary shares ‐ fully paid
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in
proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value
and the company does not have a limited amount of authorised capital.
Listed options
As part of two separate renounceable rights issues (in November 2019 and April 2020) the Company issued listed
options. In November 2019 'IBXO options' were issued with an exercise price of $0.05. In April 2020 'IBXOA options'
were issued with an exercise price of $0.03. IBXO options expire on 26 November 2021 and IBXOA options expire on
28 April 2023. Both IBXO and IBXOA options entitle the holder to convert one option to one ordinary share upon
application and payment.
3
Reserves
2021
$
109,507
2,049,768
2,159,275
Foreign currency translation reserve
Share based payment reserve
2020
$
(59,573)
1,660,862
1,601,289
Foreign currency translation reserve
The reserve is used to recognise exchange differences arising from the translation of the financial statements of
foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net
investments in foreign operations.
10
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2021
4
Commitments
The consolidated entity had contracted commitments for services in relation to its MagSenseTM HER2 breast cancer
Phase I first‐in‐human study totalling $724,164. These expenses are expected to be incurred within the next 12
months. The consolidated entity had no other commitments (31 December 2020: $718,821).
5
Contingent liabilities
As of 30 June 2021, the Company was not party to any material litigation, claims or suit whose outcome could have
a material effect on the financial statements (31 December 2020: Nil).
6
Events after the reporting period
Subsequent to year end the Company entered into a development agreement with Global Cancer Technology to
develop their nanoscintillator technology for the treatment of breast cancer. Under the terms of the agreement,
Imagion will be paid for certain R&D services while gaining an ownership interest in the arising nanoscintillator
product. The timing and quantum of any revenue associated with this agreement is unable to be determined at this
stage.
The impact of the Coronavirus (COVID‐19) pandemic is ongoing and while it has not had a significant impact on the
consolidated entity financially up to 30 June 2021 the pandemic has slowed progress with the pace of its Phase I
Clinical Study. It is not practicable to estimate the potential impact, positive or negative, after the reporting date.
The situation is constantly evolving and is dependent on measures imposed by the Australian and State‐based
Governments.
No other matters or circumstances have arisen since the end of the financial period that has significantly affected or
may significantly affect the operations of the consolidated entity, the results of those operations, or the state of
affairs of the consolidated entity in future financial years.
11
Imagion Biosystems Limited
Directors' Declaration
For the half‐year ended 30 June 2021
In the directors' opinion:
• the attached financial statements and notes comply with the Corporations Act 2001 , Australian Accounting
Standard AASB134 Interim Financial Report; the Corporations Regulations 2001 and other mandatory
professional reporting requirements;
• the attached financial statements and notes give a true and fair view of the consolidated entity's financial
position as at 30 June 2021 and of its performance for the financial half‐year ended on that date; and
• there are reasonable grounds to believe that the company will be able to pay its debts as and when they
become due and payable.
Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act
2001.
On behalf of the directors
Robert Proulx
Executive Chair
Imagion Biosystems Limited
17 August 2021
12
INDEPENDENT AUDITOR’S REVIEW REPORT
To The Members of Imagion Biosystems Limited
Report on the Half-Year Financial Report
We have reviewed the accompanying half-year financial report of Imagion Biosystems Limited (the Company)
and its Controlled Entity (the Consolidated Entity)which comprises the consolidated statement of financial position
as at 30 June 2021, the consolidated statement of comprehensive income, the consolidated statement of changes
in equity and the consolidated statement of cash flows for the half-year ended on that date, notes comprising a
summary of significant accounting policies and other explanatory information, and the directors’ declaration of the
consolidated entity comprising the company and the entity it controlled at the half-year end or from time to time
during the half-year.
Directors’ Responsibility for the Half-Year Financial Report
The directors of the company are responsible for the preparation of the half-year financial report that gives a true
and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such
internal control as the directors determine is necessary to enable the preparation of the half-year financial report
that is free from material misstatement, whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted
our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial
Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the
procedures described, we have become aware of any matter that makes us believe that the half-year financial
report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the consolidated
entity’s financial position as at 30 June 2021 and its performance for the half-year ended on that date; and
complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations
2001. As the auditor of Imagion Biosystems Limited and its Controlled Entity, ASRE 2410 requires that we comply
with the ethical requirements relevant to the audit of the annual financial report.
A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial
and accounting matters, and applying analytical and other review procedures. A review is substantially less in
scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not
enable us to obtain assurance that we would become aware of all significant matters that might be identified in an
audit. Accordingly, we do not express an audit opinion.
13
Independence
In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to
the directors of Imagion Biosystems Limited and its Controlled Entity, would be in the same terms if given to the
directors as at the time of this auditor’s report.
Conclusion
Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that
the half-year financial report of Imagion Biosystems Limited and its Controlled Entity not in accordance with the
Corporations Act 2001 including:
(a)
giving a true and fair view of the consolidated entity’s financial position as at 30 June 2021 and of its
performance for the half-year ended on that date; and
(b)
complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations
Regulations 2001.
RSM AUSTRALIA PARTNERS
R B MIANO
Partner
Dated: 17 August 2021
Melbourne, Victoria
14
Imagion Biosystems Limited
Corporate Directory
For the half‐year ended 30 June 2021
Corporate Directory
Directors
Mr Robert Proulx
Mr Michael Harsh
Mr David Ludvigson
Ms Jovanka Naumoska
Mr Mark Van Asten
Ms Dianne Angus
Executive Chairman / President
Non‐Executive Director
Non‐Executive Director
Non‐Executive Director
Non‐Executive Director
Non‐Executive Director
Company Secretary
Mr Geoff Hollis
Registered Office
c/o ‐ K&L Gates
Level 25, 525 Collins Street
Melbourne, VIC, 3000, Australia
Principal Place of Business
10355 Science Center Drive
Suite 210
San Diego, CA, 92121, USA
Share Registry
Boardroom Pty Limited
Level 12, 225 George Street
Sydney, NSW, 2000, Australia
Auditor
RSM Australia Partners
Level 21, 55 Collins St
Melbourne, VIC, 3000, Australia
Australian Legal Advisor
K&L Gates
Level 25, 525 Collins Street
Melbourne, VIC, 3000, Australia
United States Legal Advisor
The Grafe Law Office, PC
PO Box 2689
Corrales, NM, 87048, USA
Stock Exchange
Imagion Biosystems Limited's shares are listed on the Australian Stock Exchange (ASX ticker: IBX)
15
Share your feedback
Discover